Can we grow a supply of red blood cells by differentiating stem cells to replace donor blood?

2019 ◽  
Author(s):  
Lucas Vining-Recklitis Lucas Vining-Recklitis
Keyword(s):  
Stem Cells ◽  
Red Blood Cells ◽  
Blood Cells ◽  
Donor Blood

scholarly journals Merocyanine 540-sensitized photoinactivation of human erythrocytes parasitized by Plasmodium falciparum

Blood ◽  
1992 ◽  
Vol 80 (1) ◽  
pp. 21-24 ◽  
Author(s):  
OM Smith ◽  
SA Dolan ◽  
JA Dvorak ◽  
TE Wellems ◽  
F Sieber
Keyword(s):  
Stem Cells ◽  
Plasmodium Falciparum ◽  
Hematopoietic Stem Cells ◽  
Red Blood Cells ◽  
Human Blood ◽  
Blood Cells ◽  
Potential Usefulness ◽  
Hematopoietic Stem ◽  
Infected Blood ◽  
Merocyanine 540

The purpose of this study was to evaluate the photosensitizing dye merocyanine 540 (MC540) as a means for extracorporeal purging of Plasmodium falciparum-infected erythrocytes from human blood. Parasitized red blood cells bound more dye than nonparasitized cells, and exposure to MC540 and light under conditions that are relatively well tolerated by normal erythrocytes and normal pluripotent hematopoietic stem cells reduced the concentration of parasitized cells by as much as 1,000-fold. Cells parasitized by the chloroquine- sensitive HB3 clone and the chloroquine-resistant Dd2 clone of P falciparum were equally susceptible to MC540-sensitized photolysis. These data suggest the potential usefulness of MC540 in the purging of P falciparum-infected blood.

Red Blood Cells from Stem Cells

2011 ◽  
pp. 257-271
Author(s):  
Anna Rita Migliaccio ◽  
Carolyn Whitsett ◽  
Giovanni Migliaccio
Keyword(s):  
Stem Cells ◽  
Red Blood Cells ◽  
Blood Cells

scholarly journals A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going?

2020 ◽  
Vol 1 ◽  
pp. 263300402095934
Author(s):  
Morag Griffin ◽  
Richard Kelly ◽  
Alexandra Pike
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Life Expectancy ◽  
Red Blood Cells ◽  
Blood Cells ◽  
Treatment Options ◽  
White Blood Cells ◽  
Paroxysmal Nocturnal Haemoglobinuria ◽  
Complement Cascade ◽  
Future Treatments

Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra-orphan disease, which until 15 years ago had limited treatment options. Eculizumab, a monoclonal antibody that inhibits C5 in the terminal complement cascade, has revolutionised treatment for this disease, near normalising life expectancy and improving quality of life for patients. The treatment landscape of PNH is now evolving, with ravulizumab a second longer acting intravenous C5 inhibitor now licenced by the FDA and EMA. With different therapeutic targets in the complement cascade and difference modalities of treatment, including subcutaneous, oral and intravenous therapies being developed, increasing independence for patients and reducing healthcare requirements. This review discusses the current and future therapies for PNH. Lay summary Review of current and future treatments for patients with Paroxysmal Nocturnal Haemoglobinuria What is Paroxysmal Nocturnal Haemoglobinuria? Paroxysmal nocturnal haemoglobinuria (PNH) is a very rare disease. It arises from PNH stem cells in the bone marrow. In a normal bone marrow these are inactive; however, if there has been a problem in the bone marrow, the PNH stem cells can expand and make PNH red blood cells, white blood cells and platelets. The problem with these cells is that they lack the cell surface markers that usually protect them. Red blood cells are broken down in the circulation rather than the spleen, which gives rise to PNH symptoms such as abdominal pain, difficulty swallowing, erectile dysfunction and red or black urine (known as haemoglobinuria). The white blood cells and platelets are ‘stickier’ increasing the risk of blood clots. Previously life expectancy was reduced as there were limited treatment options available. What was the aim of this review? To provide an overview of current and future treatment options for PNH Which treatments are available? • Eculizumab is an treatment given through a vein (intravenous) every week for 5 weeks then every 2 weeks after this, and has been available for 13 years, improving life expectancy to near normal. • Ravulizumab is a newer intravenous treatment similar to eculizumab but is given every 8 weeks instead of every 2 weeks. In clinical studies it was comparable with eculizumab. • Future Treatments - There is new research looking at different methods of treatment delivery, including injections under the skin (subcutaneous) that patients can give themselves, treatments taken by mouth (oral) or a combination of an intravenous and oral treatment for those patients who are not optimally controlled on eculizumab or ravulizumab. What does this mean? PNH is now treatable. For years, the only drug available was eculizumab, but now different targets and drug trials are available. Ravulizumab is currently the only second licenced product available, in USA and Europe, there are other medications active in clinical trials. Why is this important? The benefit for patients, from treatment every 2 weeks to every 8 weeks is likely to be improved further with the development of these new treatments, providing patients with improved disease control and independence. As we move into an era of more patient-friendly treatment options, the PNH community both physicians and patients look forward to new developments as discussed in this article.

Dna methylation of manufactured red blood cells from human induced pluripotent stem cells

2017 ◽  
Vol 53 ◽  
pp. S111-S112
Author(s):  
Isabel Dorn ◽  
Claudia Bernecker ◽  
Slave Trajanoski ◽  
Holm Zaehres ◽  
Peter Schlenke ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Stem Cells ◽  
Red Blood Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Blood Cells ◽  
Induced Pluripotent

Generation of human induced pluripotent stem cells from a Bombay individual: Moving towards “universal-donor” red blood cells

2010 ◽  
Vol 391 (1) ◽  
pp. 329-334 ◽  
Author(s):  
Ali Seifinejad ◽  
Adeleh Taei ◽  
Mehdi Totonchi ◽  
Hamed Vazirinasab ◽  
Seideh Nafiseh Hassani ◽  
...  
Keyword(s):  
Stem Cells ◽  
Red Blood Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Blood Cells ◽  
Induced Pluripotent ◽  
Universal Donor

Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells

2005 ◽  
Vol 23 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Marie-Catherine Giarratana ◽  
Ladan Kobari ◽  
Hélène Lapillonne ◽  
David Chalmers ◽  
Laurent Kiger ◽  
...  
Keyword(s):  
Stem Cells ◽  
Hematopoietic Stem Cells ◽  
Red Blood Cells ◽  
Blood Cells ◽  
Ex Vivo ◽  
Hematopoietic Stem ◽  
Human Red Blood Cells

scholarly journals Quality of Red Blood Cells Isolated from Umbilical Cord Blood Stored at Room Temperature

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Mariia Zhurova ◽  
John Akabutu ◽  
Jason Acker
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Red Blood Cells ◽  
Future Development ◽  
Blood Cells ◽  
Room Temperature ◽  
Fetal Hemoglobin ◽  
Blood Characteristics ◽  
Rbc Transfusion

Red blood cells (RBCs) from cord blood contain fetal hemoglobin that is predominant in newborns and, therefore, may be more appropriate for neonatal transfusions than currently transfused adult RBCs. Post-collection, cord blood can be stored at room temperature for several days before it is processed for stem cells isolation, with little known about how these conditions affect currently discarded RBCs. The present study examined the effect of the duration cord blood spent at room temperature and other cord blood characteristics on cord RBC quality. RBCs were tested immediately after their isolation from cord blood using a broad panel of quality assays. No significant decrease in cord RBC quality was observed during the first 65 hours of storage at room temperature. The ratio of cord blood to anticoagulant was associated with RBC quality and needs to be optimized in future. This knowledge will assist in future development of cord RBC transfusion product.

Sign in / Sign up

Export Citation Format

Share Document